ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses

Pivotal trial demonstrated avacopan’s statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy

MOUNTAIN VIEW, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part of the virtual annual meetings of the leading European rheumatology and nephrology organizations, EULAR (European League Against Rheumatism) and ERA-EDTA (European Renal Association - European Dialysis and Transplant Association), being held June 3-6 and June 6-9, respectively.

EULAR – Open Plenary Abstract Session
Title: A Randomized, Double-Blind, Active-Controlled Study of Avacopan in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Date: Wednesday, June 3, 2020
Time: 15:10-15:20 CEST (9:10-9:20 a.m. ET)
Presenter: Dr. Peter Merkel

ERA-EDTA – Oral Presentation, Plenary
Title: A Randomized, Double-Blind, Active Controlled Study of Avacopan in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Date: Sunday, June 7, 2020
Time: 12:15-12:25 CEST (6:15-6:25 a.m. ET)
Presenter: Dr. David Jayne

About ADVOCATE and ANCA Vasculitis
The ADVOCATE trial of avacopan was a global randomized, double-blind, active-controlled, double-dummied Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive avacopan plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) or prednisone plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate). The treatment period was 52 weeks.

ANCA vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently treatment for ANCA vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with high-dose corticosteroid administration for prolonged periods of time, which can be associated with significant clinical risk including death from infection.